Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund

Executive Summary

The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.

Advertisement

Related Content

French Campaign To Boost Generics Gets Thumbs Up From European Industry Body
France Relaxes Stance On Biosimilar Switching
French Industry Rages Over €1.7bn Drug Savings Plan

Topics

Advertisement
UsernamePublicRestriction

Register